一、2025年度主要财务数据和指标 证券代码：688079 证券简称：美迪凯 公告编号：2026-006 杭州美迪凯光电科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度的定期报告为准，提请投资者注意投资风险。 单位：万元 ■ 注：1.本报告期初数同法定披露的上年年末数。 2.上述财务数据及指标为未经审计的合并报表数据，最终数据以公司2025年年度报告中披露数据为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况以及财务状况 公司2025年度实现营业收入66,438.70万元，较上年同期增加17,887.58万元，同比增长36.84%；实现归 属于母公司所有者的净利润-15,501.45万元，较上年同期亏损扩大5,316.87万元；实现归属于母公司所有 者的扣除非经常性损益的净利润-15,786.65万元，较上年同期亏损扩大6,477.93万元。 报告期末公司总资产337 ...

Group 1: Transaction Overview - The company plans to introduce strategic investor Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership) through its subsidiary Zhejiang Meidikai Optical Semiconductor Co., Ltd. [2] - The board of directors approved the proposal for capital increase and share expansion on December 10, 2025, and the relevant agreements have been signed [3]. Group 2: Transaction Progress - As of the announcement date, the company and related parties have signed the capital increase agreement and shareholder agreement, with a total cash capital increase of RMB 200 million received [3]. - Following the capital increase, the registered capital of the optical semiconductor company will increase from RMB 1,008,888,889 to RMB 1,101,447,503, and the company's shareholding will change to 82.44% [3]. Group 3: Performance Forecast - For the fiscal year 2025, the company expects to achieve approximately RMB 664.26 million in revenue, a year-on-year increase of 36.82% [8]. - The company anticipates a net loss attributable to shareholders of approximately RMB -154.41 million, a decrease of RMB 52.57 million compared to the previous year [8]. - EBITDA is projected to be around RMB 65.29 million, reflecting a year-on-year increase of 19.62% [8]. Group 4: Revenue Growth Factors - The revenue increase is attributed to higher sales in semiconductor packaging and testing, as well as new product launches contributing to additional revenue [14]. - Specific revenue contributions include an increase of approximately RMB 94.32 million from semiconductor packaging and testing and RMB 88.90 million from semiconductor acousto-optics [14]. Group 5: Cost and Expense Increases - The company has incurred higher costs due to stock incentive plans, increased interest expenses from larger borrowings, and rising depreciation costs from fixed asset investments [15][16]. - Research and development expenses have also increased, reflecting the company's commitment to new technologies and products [16].

Core Viewpoint - Medike (688079.SH) expects a significant increase in revenue for 2025, while net profit is projected to decline, indicating a mixed financial outlook for the company [1] Financial Projections - The company anticipates achieving an operating revenue of approximately 664.257 million yuan in 2025, representing an increase of about 178.746 million yuan or 36.82% year-on-year [1] - The projected net profit attributable to the parent company is expected to be around -154.414 million yuan, a decrease of approximately 52.568 million yuan compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is estimated to be around -156.947 million yuan, reflecting a decline of about 63.860 million yuan year-on-year [1] Revenue Drivers - The increase in revenue is primarily driven by a rise in semiconductor packaging and testing sales, which are expected to increase by approximately 94.322 million yuan [1] - Sales from semiconductor acousto-optic products are projected to rise by about 88.898 million yuan [1] - The company will begin mass production and delivery of semiconductor process bonding prisms in November 2025, contributing an additional revenue of around 10.969 million yuan [1] - Small-scale production of MEMS devices (MicroLED, uncooled infrared) is expected to generate an increase in sales revenue of approximately 4.256 million yuan [1]

Core Insights - The article highlights the significant progress and initiatives taken by the Bank of China Hainan Branch to support the development of the Hainan Free Trade Port through various financial services and innovations. Group 1: International Business Development - The Hainan Free Trade Port has established a cross-border capital flow management system, which is essential for high-level openness, supported by a multi-functional free trade account system and pilot policies [2] - The Bank of China Hainan Branch has launched the EF account, facilitating cross-border financial services, with 104 accounts opened and a business volume of approximately 15.7 billion RMB by the end of November [2] - The bank has seen a nearly 44% year-on-year increase in international settlement customers, with international settlement volume and cross-border RMB business volume growing by 89% and 158% respectively [3] Group 2: New Product and Service Innovations - The Bank of China Hainan Branch has been approved to conduct cross-border trade high-level opening pilot banking, enhancing its role in facilitating cross-border capital flow [3] - The bank has provided significant financial support to the Hainan Aerospace Chip Industry Group, issuing a total of 50 million RMB in loans to aid in production expansion [4] - The bank's high-tech industry loan balance reached 2.643 billion RMB, with an increase of 1.141 billion RMB this year [5] Group 3: Support for the Real Economy - The Hainan Zhongzheng Aquaculture Company has become a leading enterprise in agricultural industrialization, with significant production activities supported by the Bank of China Hainan Branch [6] - The bank has implemented a comprehensive financial service model for "Hainan Fresh Products" enterprises, providing tailored services to meet diverse financial needs [7] - The bank's technology enterprise loan balance reached 3.394 billion RMB, with a growth rate of 23.62%, and it has supported 24,100 small and micro enterprises in the past two years [7]

Core Viewpoint - The company Medike (688079) has approved a capital increase for its subsidiary, Zhejiang Medike Optical Semiconductor Co., Ltd., by introducing a strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), with an investment of 200 million yuan at a pre-investment valuation of 2.18 billion yuan [1] Group 1: Capital Increase Details - The strategic investor will hold an 8.40% stake in Medike Optical Semiconductor after the capital increase [1] - The funds from this capital increase will primarily be used for the main business of Medike Optical Semiconductor and other purposes agreed upon by the investor [1] - The capital raised cannot be transferred to Medike or its affiliates for any purpose [1] Group 2: Financial Performance - In 2024, Medike Optical Semiconductor is projected to have a revenue of 313 million yuan and a net loss of 42.47 million yuan [2] - For the first three quarters of 2025, the company reported a revenue of 264 million yuan and a net loss of 65.77 million yuan [2] Group 3: Strategic Implications - The capital increase is expected to enhance the financial strength of Medike Optical Semiconductor, meeting the capital needs for its business development and creating synergistic effects [2] - The capital increase agreement includes provisions for potential share buybacks, allowing Medike to repurchase shares from the investor within four years under certain conditions [2] - Medike remains the controlling shareholder of Medike Optical Semiconductor post-capital increase, and the subsidiary will continue to be included in Medike's consolidated financial statements [3] Group 4: Business Strategy - Medike focuses on product differentiation and is actively improving its business and product structure, investing in semiconductor optoelectronics, micro-nano circuits (mainly MEMS), semiconductor packaging and testing, precision optics, micro-nano optics, and smart terminal manufacturing [3] - The company is increasing the proportion of its products in semiconductor optoelectronics, micro-nano circuits, and semiconductor packaging and testing, optimizing its customer structure and enhancing the semiconductor device industry chain [3]

Core Viewpoint - Hainan is accelerating the construction of a modern industrial system with unique characteristics and advantages, focusing on high-quality development and the integration of technology and industry [4][8][24]. Group 1: Modern Industrial System Development - Hainan is leveraging its unique advantages to build a modern industrial system, emphasizing the optimization and upgrading of leading industries [4][10]. - The "4532" strategy is being implemented to enhance the modern industrial system, with the semiconductor industry beginning to take root in Hainan [9]. - The agricultural sector, particularly the South Seed Industry, has over 2,800 related enterprises with an annual output value exceeding 18 billion yuan [10]. Group 2: Key Industries and Economic Growth - The four leading industries in Hainan—tourism, modern services, high-tech industries, and tropical agriculture—accounted for 67% of the province's GDP in 2024, with a notable increase from 2020 [14]. - The marine economy has shown an average nominal growth rate of 13.9% over four years, contributing to 34.1% of the GDP in 2024 [11]. - The clean energy sector has achieved over 70% in power generation and 86% in installed capacity [12]. Group 3: Innovation and Technology Integration - Hainan is focusing on the deep integration of technological innovation and industrial innovation to drive significant breakthroughs and enhance productivity [17][21]. - The province has seen a rapid increase in R&D investment, reaching 10.961 billion yuan in 2024, a 22.1% increase from the previous year [21]. - Companies like Keda Xunfei are leveraging AI to enhance industrial capabilities, with over 800,000 developers engaged in the region [15]. Group 4: Strategic Initiatives and Future Prospects - Hainan is actively promoting the development of key parks such as Sanya Yazhou Bay Science and Technology City and Boao Lecheng International Medical Tourism Pilot Zone, which are crucial for industrial clustering [12][24]. - The province is exploring new economic models in deep-sea technology and low-altitude industries, aiming to establish a comprehensive low-altitude economy [23]. - The focus on biomedicine is evident with advancements in cell and gene therapy, supported by favorable policies in the Boao Lecheng area [24].

Group 1 - The second largest shareholder of Medike (688079), Hong Kong Fengsheng Jiamei (International) Investment Co., Ltd., has announced a plan to reduce its stake by up to 3% [1][3] - The planned reduction corresponds to a market value of approximately 148 million yuan based on the closing price prior to the announcement [3][4] - Medike's stock price has seen a significant increase of 55.39% from April 9 to August 18, while the overall market rose by 18.52% during the same period [3][4] Group 2 - Since its listing in 2021, Medike has faced declining annual net profits, with a notable loss in 2023 [1][5] - The company reported a net profit of approximately -159.92 million yuan in the first quarter of 2025, although this represented a reduction in losses compared to the previous year [5][6] - Medike is actively pursuing asset acquisitions to bolster its position, having completed the acquisition of 100% stakes in Haishuo Li Optoelectronics Technology (Suzhou) Co., Ltd. and INNOWAVE VIETNAM CO., LTD. [6]

Investment Rating - The report assigns a "Buy" rating to the company, expecting the stock price to outperform the industry index by over 15% in the next six months [4][19]. Core Views - The company is acquiring 100% equity of KEM TECH CORP's subsidiary, Haisholi Optoelectronics Technology (Suzhou) Co., Ltd., for 2 billion KRW, and 100% equity of INNOWAVE VIETNAM CO., LTD. for 1 billion KRW, enhancing its overseas presence and entering the Samsung supply chain [1][2]. - The acquisitions are expected to strengthen the company's position in the optical electronics and semiconductor sectors, particularly in the Korean market, which is a strategic focus for overseas expansion [2]. - The company reported a revenue of 1.49 billion CNY in Q1 2025, a year-on-year increase of 29.02%, with a reduction in net losses, indicating improved profitability [3]. Financial Summary - Revenue projections show a growth trajectory from 321 million CNY in 2023 to 1,298 million CNY in 2027, with a compound annual growth rate (CAGR) of approximately 51.4% in 2024 [1][11]. - The net profit is expected to turn positive by 2026, with estimates of -81 million CNY in 2025, 153 million CNY in 2026, and 225 million CNY in 2027 [1][9]. - The company's return on equity (ROE) is projected to improve from -7.6% in 2024 to 13.5% in 2027, reflecting a recovery in profitability [1][11]. Market Position and Product Development - The company is focusing on semiconductor optoelectronics, MEMS, and precision optics, with products being developed for various applications including communication, consumer electronics, and smart vehicles [9]. - The report highlights the increasing penetration of periscope lenses in high-end smartphones, projecting the market size for periscope cameras in China to reach 287.2 billion CNY by 2025 [8]. - The company has developed several optical components and solutions, including diffraction optical elements and optical micro-lens arrays, which are expected to enhance its competitive edge in the market [8].

Group 1: Company Performance - The company's 2024 revenue reached 662.14 million CNY, representing an 18.04% increase compared to the previous year [5] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 55.10 million CNY, reflecting a 12.17% growth year-on-year [5] - The revenue from the machine vision equipment business grew by 7.42% last year [6] Group 2: Market Outlook - The machine vision market in China is projected to reach 56.5 billion CNY by 2027, with significant growth in 3D technology applications [3] - The current industry penetration rate is below 10%, indicating substantial growth potential, especially in semiconductor packaging and new energy vehicles [3] - The demand for high-precision and high-efficiency detection will drive technological iterations and market expansion [3] Group 3: Technological Advancements - The company has integrated AI algorithms with machine vision technology, enhancing defect detection efficiency and adaptability [2] - New products, such as dual-sided 3D AOI and semiconductor AOI devices, have been developed to meet market demands [6] - The company is exploring advanced applications of AOI+AI and AXI+AI to improve product performance and reliability [6] Group 4: Strategic Initiatives - The company is expanding its international presence with factories in Malaysia and other regions to mitigate the impact of US-China trade tensions [8] - A focus on continuous product innovation and customer needs is central to the company's strategy for maintaining competitive advantage [6] - The company aims to enhance brand influence and market share through improved service capabilities and product offerings [10] Group 5: Financial Management - The accounts receivable accounted for approximately 40% of the revenue, which is considered a reasonable level [10] - The company has a strong customer base, with over 90% of accounts receivable aging within one year, minimizing bad debt risks [10] - The company is implementing measures to strengthen accounts receivable management and improve cash flow [10]